Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Compass Therapeutics, Inc.

Market Cap 369M 321M 295M 278M 520M 34.89B 526M 3.51B 1.36B 17.14B 1.39B 1.36B 59.27B P/E 2026 *
-4.68x
P/E 2027 * -4.41x
Enterprise Value 219M 190M 175M 165M 309M 20.72B 312M 2.08B 808M 10.18B 823M 805M 35.19B EV / Sales 2026 *
-98.9x
EV / Sales 2027 * 9.24x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+4.06%
1 week-0.49%
Current month-13.87%
1 month+10.22%
3 months-62.11%
6 months-60.88%
Current year-61.82%
1 week 1.88
Extreme 1.88
2.14
1 month 1.75
Extreme 1.7506
2.47
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 56 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Date Insider Type Main position Quantity % Market Cap.
04-28Buy

Controller/Auditor

15,000 0.0083%
04-28Buy

General Counsel

25,000 0.0139%
02-07Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+4.06%-0.49%-13.50%-33.66% 355M
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.04%+6.61%-13.27%-18.06% 22.63B
+3.07%-0.60%-3.09%+392.25% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
+0.65%-1.04%+25.60%+174.70% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.27%+4.82%+75.35%+104.79% 11.56B
Average +1.34%-0.28%+21.29%+77.19% 21.01B
Weighted average by Cap. +1.53%+0.17%+31.55%+90.47%

Financials

2026 *2027 *
Net sales -2.22M -1.93M -1.77M -1.67M -3.12M -209M -3.16M -21.06M -8.17M -103M -8.31M -8.14M -356M 25.67M 22.31M 20.52M 19.3M 36.19M 2.43B 36.59M 244M 94.66M 1.19B 96.35M 94.29M 4.12B
Net income -82.94M -72.08M -66.29M -62.36M -117M -7.84B -118M -789M -306M -3.85B -311M -305M -13.32B -89.85M -78.08M -71.82M -67.56M -127M -8.49B -128M -854M -331M -4.17B -337M -330M -14.43B
Net Debt -150M -130M -120M -113M -211M -14.18B -214M -1.43B -553M -6.96B -563M -551M -24.08B -132M -115M -106M -99.25M -186M -12.48B -188M -1.26B -487M -6.13B -495M -485M -21.19B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
17/06/26 2.050 $ +4.06% 3,735,659
16/06/26 1.970 $ -3.43% 2,532,656
15/06/26 2.040 $ +0.49% 2,174,768
12/06/26 2.030 $ +1.00% 2,049,688
11/06/26 2.010 $ +4.69% 3,589,309
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
1.970USD
Average target price
8.818USD
Spread / Average Target
+347.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!